About
Built for the biology that does not fit static structure
Peptone is building a Product Engine to generate small-molecule drug candidates against intrinsically disordered proteins
Our interdisciplinary team spans academic science and pharmaceutical research, connecting measured protein dynamics with experimentally grounded models, candidate design, and biological validation.
Vision
00:00 40:20
Kamil Tamiola and Hussein Kanji discuss the scientific conviction and company-building ideas behind Peptone with Taplow Blue Capital.
Investors
Our backers saw what we saw: the proteins medicine called undruggable were never impossible, only unmeasured
F-Prime Capital, Bessemer Venture Partners, Hoxton Ventures, Walden Catalyst and the Banga Family Trust joined us at the point where physics becomes biology, to turn a class of targets others avoided into a category we intend to define.
Disordered proteins matter in biology but lack a constant binding pocket. Peptone's platform pairs the accuracy of experiment with the efficiency of in-silico modeling to unlock these targets.
We had studied ML-based drug discovery for years, and Peptone's approach immediately stood out: a computational-physics platform uniquely suited to the structural dynamics of these difficult-to-drug proteins.
Kamil is a mission-driven founder who have made this problem his life's work. We see in him the potential to build a category-defining company for drug development.
Backed by